title: Valproate attenuates the development of morphine antinociceptive tolerance.
abstract: Morphine is a potent opioid analgesic. Repeated administration of morphine induces tolerance, thus reducing the effectiveness of analgesic treatment. Although some adjuvant analgesics can increase morphine analgesia, the precise molecular mechanism behind their effects remains unclear. Opioids bind to the mu opioid receptor (MOR). Morphine tolerance may be derived from alterations in the intracellular signal transduction after MOR activation. Chronic morphine treatment activates glycogen synthase kinase 3β (GSK3β), whose inhibition diminishes morphine tolerance. Valproate is widely prescribed as an anticonvulsant and a mood stabilizer for bipolar disorders because it increases the amount of γ-aminobutyric acid (GABA) in the central nervous system. Although the activation of GABAergic neurons may be responsible for the chief pharmacologic effect of valproate, recent studies have shown that valproate also suppresses GSK3β activity. We examined the effect of valproate on the development of morphine antinociceptive tolerance in a mouse model of thermal injury. Mice were treated with morphine alone or with morphine and valproate twice daily for 5 days. The resulting antinociceptive effects were assessed using a hot plate test. While mice treated with morphine developed tolerance, co-administration of valproate attenuated the development of tolerance and impaired the activation of GSK3β in mice brains. Valproate alone did not show analgesic effects; nevertheless, it functioned as an adjuvant analgesic to prevent the development of morphine tolerance. These results suggest that the modulation of GSK3β activity by valproate may be useful and may play a role in the prevention of morphine tolerance.
authors.affiliation: Department of Anesthesiology, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan.
authors.forename: Tamae
authors.initials: T
authors.lastname: Dobashi
authors.forename: Serabi
authors.initials: S
authors.lastname: Tanabe
authors.forename: Hisayo
authors.initials: H
authors.lastname: Jin
authors.forename: Takashi
authors.initials: T
authors.lastname: Nishino
authors.forename: Tomohiko
authors.initials: T
authors.lastname: Aoe
mesh_terms: D000700:Analgesics / Q000494:pharmacology; D000818:Animals; D004361:Drug Tolerance / Q000502:physiology*; D018682:GABA Agents / Q000494:pharmacology; D038362:Glycogen Synthase Kinase 3 / Q000037:antagonists & inhibitors / Q000378:metabolism; D000071679:Glycogen Synthase Kinase 3 beta; D006358:Hot Temperature / Q000009:adverse effects; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009020:Morphine / Q000633:toxicity; D009021:Morphine Dependence / Q000188:drug therapy* / Q000201:enzymology; D010147:Pain Measurement / Q000187:drug effects / Q000379:methods; D017288:Pain Threshold / Q000187:drug effects / Q000502:physiology; D014635:Valproic Acid / Q000494:pharmacology*
chemical_list: D000700:Analgesics; D018682:GABA Agents; D014635:Valproic Acid; D009020:Morphine; D000071679:Glycogen Synthase Kinase 3 beta; C000605507:Gsk3b protein, mouse; D038362:Glycogen Synthase Kinase 3